Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $13.50, up 3.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNTA shares have gain 5.06% over the last week, with a monthly amount glided 31.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on July 18, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $14. Previously, Jefferies upgraded its rating to Buy on November 15, 2023, and elevated its price target to $11. On October 26, 2023, upgrade upgraded it’s rating to Equal-Weight and revised its price target to $8 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating. Guggenheim initiated its recommendation with a Buy and recommended $9 as its price target on June 12, 2023. SVB Securities started tracking with a Outperform rating for this stock on March 17, 2023, and assigned it a price target of $6. In a note dated August 12, 2022, Morgan Stanley downgraded an Underweight rating on this stock and revised its target price from $10 to $5.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $5.15 and $14.48 over the past year. Currently, Wall Street analysts expect the stock to reach $15 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $13.50 at the most recent close of the market. An investor can expect a potential return of 11.11% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -22.54%, Pretax Profit Margin comes in at -22.88%, and Net Profit Margin reading is -22.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.63 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.08 points at the first support level, and at 12.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.79, and for the 2nd resistance point, it is at 14.08.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 13.29. In addition, the Quick Ratio stands at 13.29 and the Cash Ratio stands at 4.76. Considering the valuation of this stock, the price to sales ratio is 221.12, the price to book ratio is 5.32.
Transactions by insiders
Recent insider trading involved SAHA SAURABH, Chief Executive Officer, that happened on Aug 23 ’24 when 46651.0 shares were sold. Chief Business Officer, Weinhoff Gregory M completed a deal on Aug 23 ’24 to sell 17802.0 shares. Meanwhile, Chief Business Officer Weinhoff Gregory M sold 12198.0 shares on Aug 22 ’24.
